Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Randomized open label clinical trial carried out at study centers in Sweden, including
Karolinska University Hospital, S:t Göran Hospital, Danderyd Hospital and Västmanlands
Hospital. Patients with COVID-19 who are hospitalized with oxygen therapy are eligible for
inclusion. Subjects are randomized to 14 days of inhalation with ciclesonide 360 µg twice
daily or to standard of care. Primary outcome is duration of received supplemental oxygen
therapy. Key secondary outcome is a composite outcome of death and received invasive
mechanical ventilation within 30 days.
Phase:
Phase 2
Details
Lead Sponsor:
Ola Blennow, MD, PhD
Collaborators:
Centrallasarettet Västerås Danderyd Hospital Karolinska University Hospital